BNTC Stock Analysis: Buy, Sell, or Hold?
BNTC - Benitec Biopharma Inc. Common Stock
$12.15
0.44 (3.76%)
▲
5d:
+4.92%
30d:
-8.09%
90d:
+1.67%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Sep 22, 2026
Get Alerted When BNTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BNTC shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: BNTC shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: BNTC is currently trading at $12.15, which is considered slightly low relative to its 30-day fair value range of $11.83 to $13.23.
Technical Outlook: Technically, BNTC is in a uptrend. The price is approaching resistance at $12.42. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (15th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.17 (+98.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BNTC is in a uptrend. The price is approaching resistance at $12.42. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (15th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.17 (+98.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$11.83 -
$13.23
Company Quality Score
51/100
(HOLD)
Options IV Signal
15th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
90.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 15th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 98.9% below Wall St target ($24.17)
Trading Range Analysis
30-Day Trading Range
$11.83 -
$13.23
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$2.24
(18.5%)
Support & Resistance Levels
Support Level
$11.10
Resistance Level
$12.42
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.63
Wall Street Target
$24.17
(+98.9%)
Revenue Growth (YoY)
12.5%
Share & Embed Analysis
Last updated: August 03, 2026 6:09 PM ET
Data refreshes hourly during market hours. Next update: 7:09 PM
Data refreshes hourly during market hours. Next update: 7:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BNTC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
